Endothelial cell control of thrombosis

BMC Cardiovascular Disorders

Subodh Verma¹  Hwee Teoh³  Jonathan W. Yau² 

[1] Department of Surgery, University of Toronto, Toronto, ON, Canada;Division of Cardiac Surgery, St. Michael’s Hospital, Bond Wing, 30 Bond St., Toronto M5B 1W8, ON, Canada;Divisions of Endocrinology & Metabolism, Keenan Research Centre for Biomedical Science at St. Michael’s Hospital, Toronto, ON, Canada

关键词: Blood coagulation;    Thrombosis;    Endothelial cells;   

Others  :  1228945
DOI  :  10.1186/s12872-015-0124-z

 received in 2015-05-11, accepted in 2015-10-09,  发布年份 2015

【 摘 要 】

Hemostasis encompasses a set of tightly regulated processes that govern blood clotting, platelet activation, and vascular repair. Upon vascular injury, the hemostatic system initiates a series of vascular events and activates extravascular receptors that act in concert to seal off the damage. Blood clotting is subsequently attenuated by a plethora of inhibitors that prevent excessive clot formation and eventual thrombosis. The endothelium which resides at the interface between the blood and surrounding tissues, serves an integral role in the hemostatic system. Depending on specific tissue needs and local stresses, endothelial cells are capable of evoking either antithrombotic or prothrombotic events. Healthy endothelial cells express antiplatelet and anticoagulant agents that prevent platelet aggregation and fibrin formation, respectively. In the face of endothelial dysfunction, endothelial cells trigger fibrin formation, as well as platelet adhesion and aggregation. Finally, endothelial cells release pro-fibrinolytic agents that initiate fibrinolysis to degrade the clot. Taken together, a functional endothelium is essential to maintain hemostasis and prevent thrombosis. Thus, a greater understanding into the role of the endothelium can provide new avenues for exploration and novel therapies for the management of thromboembolisms.

【 授权许可】

   
2015 Yau et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Wolinsky H: A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res 1980, 47:301-311.
• [2]Mackman N: Triggers, targets and treatments for thrombosis. Nature 2008, 451:914-918.
• [3]Mackman N: New insights into the mechanisms of venous thrombosis. J Clin Invest 2012, 122:2331-2336.
• [4]Aird WC: Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007, 100:158-173.
• [5]Monahan-Earley R, Dvorak AM, Aird WC: Evolutionary origins of the blood vascular system and endothelium. J Thromb Haemost 2013, 11(Suppl 1):46-66.
• [6]Balda MS, Matter K: Tight junctions. J Cell Sci 1998, 111(Pt 5):541-547.
• [7]Cotran RS, Pober JS: Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990, 1:225-235.
• [8]Ebnet K, Vestweber D: Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Histochem Cell Biol 1999, 112:1-23.
• [9]Pearson JD: Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999, 12:329-341.
• [10]van Hinsbergh VW: Endothelium--role in regulation of coagulation and inflammation. Semin Immunopathol 2012, 34:93-106.
• [11]Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al.: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
• [12]Pober JS, Sessa WC: Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007, 7:803-815.
• [13]Lin Z, Kumar A, SenBanerjee S, Staniszewski K, Parmar K, Vaughan DE, et al.: Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 2005, 96:e48-e57.
• [14]Zhou G, Hamik A, Nayak L, Tian H, Shi H, Lu Y, et al.: Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest 2012, 122:4727-4731.
• [15]Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, et al.: Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003, 100:10623-10628.
• [16]Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT: Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 1997, 96:3633-3640.
• [17]Aird WC: Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007, 100:174-190.
• [18]Versteeg HH, Heemskerk JW, Levi M, Reitsma PH: New fundamentals in hemostasis. Physiol Rev 2013, 93:327-358.
• [19]Davis SF, Yeung AC, Meredith IT, Charbonneau F, Ganz P, Selwyn AP, et al.: Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996, 93:457-462.
• [20]MacFarlane RG: An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964, 202:498-499.
• [21]Bode MF, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2014;35.
• [22]Drake TA, Morrissey JH, Edgington TS: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989, 134:1087-1097.
• [23]Owens AP III, Mackman N: Role of tissue factor in atherothrombosis. Curr Atheroscler Rep 2012, 14:394-401.
• [24]Borissoff JI, Spronk HM, ten Cate H: The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011, 364:1746-1760.
• [25]Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, et al.: Identification of active tissue factor in human coronary atheroma. Circulation 1996, 94:1226-1232.
• [26]Tremoli E, Camera M, Toschi V, Colli S: Tissue factor in atherosclerosis. Atherosclerosis 1999, 144:273-283.
• [27]Parry GC, Mackman N: Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995, 15:612-621.
• [28]Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al.: Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983, 71:1893-1896.
• [29]Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986, 83:4533-4537.
• [30]Houston P, Dickson MC, Ludbrook V, White B, Schwachtgen JL, McVey JH, et al.: Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol 1999, 19:281-289.
• [31]Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, et al.: Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001, 15:230-242.
• [32]Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, et al.: Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 2002, 99:199-206.
• [33]Zhou L, Stordeur P, de Lavareille A, Thielemans K, Capel P, Goldman M, et al.: CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 1998, 79:1025-1028.
• [34]Miller DL, Yaron R, Yellin MJ: CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1998, 63:373-379.
• [35]Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G: Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998, 80:1008-1014.
• [36]Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U: Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002, 277:25032-25039.
• [37]Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005, 52:1545-1554.
• [38]Del Turco S, Basta G, Lazzerini G, Chancharme L, Lerond L, De Caterina R: Involvement of the TP receptor in TNF-alpha-induced endothelial tissue factor expression. Vascul Pharmacol 2014, 62:49-56.
• [39]Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U: Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005, 96:1233-1239.
• [40]Bode M, Mackman N: Regulation of tissue factor gene expression in monocytes and endothelial cells: thromboxane A2 as a new player. Vascul Pharmacol 2014, 62:57-62.
• [41]Semeraro N, Triggiani R, Montemurro P, Cavallo LG, Colucci M: Enhanced endothelial tissue factor but normal thrombomodulin in endotoxin-treated rabbits. Thromb Res 1993, 71:479-486.
• [42]Song D, Ye X, Xu H, Liu SF: Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. Blood 2009, 114:2521-2529.
• [43]Erlich J, Fearns C, Mathison J, Ulevitch RJ, Mackman N: Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 1999, 67:2540-2546.
• [44]Pawlinski R, Pedersen B, Kehrle B, Aird WC, Frank RD, Guha M, et al.: Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood 2003, 101:3940-3947.
• [45]Chen VM, Hogg PJ: Encryption and decryption of tissue factor. J Thromb Haemost 2013, 11(Suppl 1):277-284.
• [46]Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, Hebbel RP, Monroe DM, et al.: Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 2014, 123:1747-1756.
• [47]Arderiu G, Pena E, Badimon L: Angiogenic microvascular endothelial cells release microparticles rich in tissue factor that promotes postischemic collateral vessel formation. Arterioscler Thromb Vasc Biol 2015, 35:348-357.
• [48]Schousboe I: Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem 2003, 270:111-118.
• [49]Webster WP, Zukoski CF, Hutchin P, Reddick RL, Mandel SR, Penick GD: Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol 1971, 220:1147-1154.
• [50]Do H, Healey JF, Waller EK, Lollar P: Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999, 274:19587-19592.
• [51]Norman JC, Covelli VH, Sise HS: Transplantation of the spleen: experimental cure of hemophilia. Surgery 1968, 64:1-14.
• [52]Veltkamp JJ, Asfaou E, van de Torren K, van der Does JA, van Tilburg NH, Pauwels EK: Extrahepatic factor VIII synthesis. Lung transplants in hemophilic dogs. Transplantation 1974, 18:56-62.
• [53]Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR: A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014, 123:3706-3713.
• [54]Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D: Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014, 123:3697-3705.
• [55]Wagner DD, Marder VJ: Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984, 99:2123-2130.
• [56]Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B: Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007, 117:953-960.
• [57]Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ: The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995, 85:3150-3157.
• [58]Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, et al.: A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A 1998, 95:9524-9529.
• [59]Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al.: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006, 4:2103-2114.
• [60]Giblin JP, Hewlett LJ, Hannah MJ: Basal secretion of von Willebrand factor from human endothelial cells. Blood 2008, 112:957-964.
• [61]Johnsen J, Lopez JA: VWF secretion: what’s in a name? Blood 2008, 112:926-927.
• [62]Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB: Thrombin-mediated release of factor VIII antigen from human umbilical vein endothelial cells in culture. Blood 1982, 60:531-534.
• [63]Rusu L, Andreeva A, Visintine DJ, Kim K, Vogel SM, Stojanovic-Terpo A, et al.: G protein-dependent basal and evoked endothelial cell vWF secretion. Blood 2014, 123:442-450.
• [64]Torisu T, Torisu K, Lee IH, Liu J, Malide D, Combs CA, et al.: Autophagy regulates endothelial cell processing, maturation and secretion of von Willebrand factor. Nat Med 2013, 19:1281-1287.
• [65]Dmitrieva NI, Burg MB: Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis. Proc Natl Acad Sci U S A 2014, 111:6485-6490.
• [66]Watson SP: Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. Curr Pharm Des 2009, 15:1358-1372.
• [67]Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, et al.: The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a Par gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 1998, 273:15061-15068.
• [68]O’Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, et al.: Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000, 275:13502-13509.
• [69]Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, et al.: Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 2011, 130:248-282.
• [70]Coughlin SR: Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
• [71]Coughlin SR: Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005, 3:1800-1814.
• [72]Esmon CT, Esmon NL: The link between vascular features and thrombosis. Annu Rev Physiol 2011, 73:503-514.
• [73]Wood JP, Ellery PE, Maroney SA, Mast AE: Biology of tissue factor pathway inhibitor. Blood 2014, 123:2934-2943.
• [74]Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988, 50:803-813.
• [75]Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH: Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000, 83:937-943.
• [76]Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999, 19:2251-2262.
• [77]Wood JP, Ellery PE, Maroney SA, Mast AE: Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2014, 34:169-176.
• [78]Huang ZF, Higuchi D, Lasky N, Broze GJ Jr: Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997, 90:944-951.
• [79]White TA, Johnson T, Zarzhevsky N, Tom C, Delacroix S, Holroyd EW, et al.: Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood 2010, 116:1787-1794.
• [80]Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM: Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003, 101:4387-4392.
• [81]Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, et al.: Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004, 109:1343-1348.
• [82]Martin FA, McLoughlin A, Rochfort KD, Davenport C, Murphy RP, Cummins PM: Regulation of thrombomodulin expression and release in human aortic endothelial cells by cyclic strain. PLoS One 2014, 9:e108254.
• [83]Anastasiou G, Gialeraki A, Merkouri E, Politou M, Travlou A: Thrombomodulin as a regulator of the anticoagulant pathway: implication in the development of thrombosis. Blood Coagul Fibrinolysis 2012, 23:1-10.
• [84]Griffin JH, Zlokovic BV, Mosnier LO: Protein C anticoagulant and cytoprotective pathways. Int J Hematol 2012, 95:333-345.
• [85]Owen WG, Esmon CT: Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1981, 256:5532-5535.
• [86]Fukudome K, Esmon CT: Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994, 269:26486-26491.
• [87]Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT: The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A 1996, 93:10212-10216.
• [88]Fukudome K, Kurosawa S, Stearns-Kurosawa DJ, He X, Rezaie AR, Esmon CT: The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem 1996, 271:17491-17498.
• [89]Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, et al.: Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 2002, 277:43335-43343.
• [90]Collen D, Lijnen HR: The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009, 29:1151-1155.
• [91]Rijken DC, Lijnen HR: New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009, 7:4-13.
• [92]Huber D, Cramer EM, Kaufmann JE, Meda P, Masse JM, Kruithof EK, et al.: Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002, 99:3637-3645.
• [93]Emeis JJ, Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F: An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997, 139:245-256.
• [94]Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, et al.: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368:419-424.
• [95]Lijnen HR, Moons L, Beelen V, Carmelie P, Collen D: Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice. Thromb Haemost 1995, 74:1126-1131.
• [96]Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM: The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemost 1990, 63:476-481.
• [97]Chung DW, Fujikawa K: Processing of von Willebrand factor by ADAMTS-13. Biochemistry 2002, 41:11065-11070.
• [98]Turner N, Nolasco L, Tao Z, Dong JF, Moake J: Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006, 4:1396-1404.
• [99]Moake JL: Thrombotic microangiopathies. N Engl J Med 2002, 347:589-600.
• [100]Petraglia AL, Marky AH, Walker C, Thiyagarajan M, Zlokovic BV: Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact. Neurosurgery 2010, 66:165-171.
• [101]Ribes JA, Ni F, Wagner DD, Francis CW: Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest 1989, 84:435-442.
• [102]Shaikh FM, Callanan A, Kavanagh EG, Burke PE, Grace PA, McGloughlin TM: Fibrin: a natural biodegradable scaffold in vascular tissue engineering. Cells Tissues Organs 2008, 188:333-346.
• [103]Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K, et al.: Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002, 91:25-31.
• [104]Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al.: Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
• [105]Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F: Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 2011, 9(Suppl 1):306-315.
• [106]Belting M, Ahamed J, Ruf W: Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005, 25:1545-1550.
• [107]Folkman J: Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167-168.
• [108]Giannarelli C, Alique M, Rodriguez DT, Yang DK, Jeong D, Calcagno C, et al.: Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1alpha and vascular endothelial growth factor signaling. Circulation 2014, 130:1274-1286.
• [109]Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, et al.: Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007, 120(Suppl 2):S13-S21.
• [110]van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, et al.: Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci U S A 2009, 106:19497-19502.
• [111]Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI: Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A 1991, 88:708-712.
• [112]Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI: Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991, 78:1496-1502.